Company / Net Income
Syndax Pharmaceuticals Inc Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$285.4M
FY2025
5-year range
-$318.8M / -$56.0M
FY2021-FY2025
Trend
+10.5%
vs FY2024
Sector context
#175 of 216
Health Care
What the data says
Syndax Pharmaceuticals Inc's net income of -$285M is lower than 81% of companies in the Health Care sector (FY2025). Net Income returned to growth in FY2025 after 3 years of decline, reaching -$285M.
Based on SEC 10-K filings.
-$285M in FY2025.
Declined from -$209M to -$285M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 216This company -$285.4M Sector average $454.3M
▼
-162.8% below sector average
Key checks
Key Insights
- In FY2025, net income increased 10.5% year-over-year.
- Ranks #175 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$285.4M | +10.5% |
| FY2024 | -$318.8M | -52.3% |
| FY2023 | -$209.4M | -40.2% |
| FY2022 | -$149.3M | -166.5% |
| FY2021 | -$56.0M | +24.2% |
| FY2020 | -$74.0M | -21.6% |
| FY2019 | -$60.8M | -36.7% |
| FY2018 | -$44.5M | -84.4% |
| FY2017 | -$24.1M | -21.6% |
| FY2016 | -$19.8M | +17.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026